Target isoforms are an overlooked challenge and opportunity in chimeric antigen receptor cell therapy

Mike Bogetofte Barnkob; Kristoffer Vitting-Seerup; Lars Rønn Olsen

doi:10.1093/immadv/ltac009

Target isoforms are an overlooked challenge and opportunity in chimeric antigen receptor cell therapy

Mike Bogetofte Barnkob, Kristoffer Vitting-Seerup, Lars Rønn Olsen^*

^*Corresponding author for this work

Odense University Hospital

Research output: Contribution to journal › Journal article › Research › peer-review

17 Downloads (Pure)

Abstract

The development of novel chimeric antigen receptor (CAR) cell therapies is rapidly growing, with 299 new agents being reported and 109 new clinical trials initiated so far this year. One critical lesson from approved CD19-specific CAR therapies is that target isoform switching has been shown to cause tumour relapse, but little is known about the isoforms of CAR targets in solid cancers. Here we assess the protein isoform landscape and identify both the challenges and opportunities protein isoform switching present as CAR therapy is applied to solid cancers.

Original language	English
Article number	Itac009
Journal	Immunotherapy Advances
Volume	2
Issue number	1
Number of pages	4
ISSN	2732-4303
DOIs	https://doi.org/10.1093/immadv/ltac009
Publication status	Published - 2022

Keywords

Chimeric antigen receptor therapy
Isoform switching
Epitopes
Cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/immadv/ltac009Licence: CC BY-NC

FulltextFinal published version, 4.93 MBLicence: CC BY-NC

OpenUrl availability

Full text

Cite this

@article{cfc5c2d3ef1646b2b51770b6f805dd6f,

title = "Target isoforms are an overlooked challenge and opportunity in chimeric antigen receptor cell therapy",

abstract = "The development of novel chimeric antigen receptor (CAR) cell therapies is rapidly growing, with 299 new agents being reported and 109 new clinical trials initiated so far this year. One critical lesson from approved CD19-specific CAR therapies is that target isoform switching has been shown to cause tumour relapse, but little is known about the isoforms of CAR targets in solid cancers. Here we assess the protein isoform landscape and identify both the challenges and opportunities protein isoform switching present as CAR therapy is applied to solid cancers.",

keywords = "Chimeric antigen receptor therapy, Isoform switching, Epitopes, Cancer",

author = "{Bogetofte Barnkob}, Mike and Kristoffer Vitting-Seerup and {R{\o}nn Olsen}, Lars",

year = "2022",

doi = "10.1093/immadv/ltac009",

language = "English",

volume = "2",

journal = "Immunotherapy Advances",

issn = "2732-4303",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Target isoforms are an overlooked challenge and opportunity in chimeric antigen receptor cell therapy

AU - Bogetofte Barnkob, Mike

AU - Vitting-Seerup, Kristoffer

AU - Rønn Olsen, Lars

PY - 2022

Y1 - 2022

N2 - The development of novel chimeric antigen receptor (CAR) cell therapies is rapidly growing, with 299 new agents being reported and 109 new clinical trials initiated so far this year. One critical lesson from approved CD19-specific CAR therapies is that target isoform switching has been shown to cause tumour relapse, but little is known about the isoforms of CAR targets in solid cancers. Here we assess the protein isoform landscape and identify both the challenges and opportunities protein isoform switching present as CAR therapy is applied to solid cancers.

AB - The development of novel chimeric antigen receptor (CAR) cell therapies is rapidly growing, with 299 new agents being reported and 109 new clinical trials initiated so far this year. One critical lesson from approved CD19-specific CAR therapies is that target isoform switching has been shown to cause tumour relapse, but little is known about the isoforms of CAR targets in solid cancers. Here we assess the protein isoform landscape and identify both the challenges and opportunities protein isoform switching present as CAR therapy is applied to solid cancers.

KW - Chimeric antigen receptor therapy

KW - Isoform switching

KW - Epitopes

KW - Cancer

U2 - 10.1093/immadv/ltac009

DO - 10.1093/immadv/ltac009

M3 - Journal article

C2 - 35919495

SN - 2732-4303

VL - 2

JO - Immunotherapy Advances

JF - Immunotherapy Advances

IS - 1

M1 - Itac009

ER -

Target isoforms are an overlooked challenge and opportunity in chimeric antigen receptor cell therapy

Abstract

Keywords

UN SDGs

Access to Document

OpenUrl availability

Fingerprint

Cite this